2365172-19-4
Chemical Structure
XZ739
- CAS No.: 2365172-19-4
- Formula:C65H76ClF3N8O12S3
- Molecular Weight:1349.99
IUPAC Name: 4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-(((15R)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-12-methyl-16-(phenylthio)-3,6,9-trioxa-12-azahexadecan-15-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide
InChIKey: RTASGZOITGGVPZ-YJUSKGKKSA-N
SMILES: O=C(C1=CC=C(N2CCN(CC3=C(C4=CC=C(Cl)C=C4)CCC(C)(C)C3)CC2)C=C1)NS(C5=CC(S(=O)(C(F)(F)F)=O)=C(N[C@@H](CSC6=CC=CC=C6)CCN(C)CCOCCOCCOCCNC7=C8C(C(N(C9CCC(NC9=O)=O)C8=O)=O)=CC=C7)C=C5)(=O)=O
Biological Activity: XZ739 is a potent and selective BCL-XL PROTAC degrader with a DC50 of 2.5 nM. XZ739 recruits CRBN to ubiquitinate and degrade BCL-XL via the ubiquitin-proteasome system. XZ739 also induces cell cycle arrest and caspase-mediated apoptosis. XZ739 can be used in research related to T-cell acute lymphoblastic leukemia and cholangiocarcinoma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
XZ739 | 99.08% | XZ739 is a potent and selective BCL-XL PROTAC degrader with a DC50 of 2.5 nM. XZ739 recruits CRBN to ubiquitinate and degrade BCL-XL via the ubiquitin-proteasome system. XZ739 also induces cell cycle arrest and caspase-mediated apoptosis. XZ739 can be used in research related to T-cell acute lymphoblastic leukemia and cholangiocarcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhang X, et al. Discovery of PROTAC BCL-X degraders as potent anticancer agents with low on-target platelet toxicity. European journal of medicinal chemistry. 2020 Apr 15;192:112186. [Content Brief]
- [2]. Zeng Q, et al. Targeting BCL-XL for degradation synergizes with gemcitabine against cholangiocarcinoma. BMC medicine. 2026 Jan 30;24(1):126. [Content Brief]
- [3]. Zhang Z, et al. Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment. European journal of medicinal chemistry. 2022 Mar 15;232:114184. [Content Brief]
